on behalf of the ESADA Network BACKGROUND: The impact of treating OSA on renal function decline is controversial. Previous studies usually included small samples and did not consider specific effects of different CPAP modalities. The aim of this study was to evaluate the respective influence of fixed and autoadjusting CPAP modes on estimated glomerular filtration rate (eGFR) in a large sample of patients derived from the prospective European Sleep Apnea Database cohort.
OSA is a chronic disorder causing disabling symptoms, such as excessive daytime sleepiness, nonrestorative sleep, and nocturnal choking. 1 The high prevalence of OSA and its cardiometabolic comorbidities make it a burden for society. 2 Longitudinal observational studies supported a causal association between OSA and cardiovascular or metabolic diseases. 3, 4 A link between OSA and decline in renal function is still debated. Cross-sectional studies have reported that glomerular filtration rate (GFR) assessed by using estimative equations (eGFR) is 5, 6 -or is not 7-9 -related to the apnea/hypopnea index, or to indices of nocturnal hypoxemia. 9, 10 More consistent results have been provided by long-term longitudinal studies. Two longitudinal studies with polysomnographic documentation of OSA severity found a faster decline in eGFR in OSA subgroups with the most severe disease. 11, 12 Three national database studies showed a higher incidence of chronic kidney disease (CKD) in patients with OSA compared with control subjects. [13] [14] [15] However, little is known about the long-term effects of OSA treatment on eGFR.
CPAP is the first-line therapy for OSA, normalizing symptoms and improving quality of life. 16 Although large, long-term studies did not show a positive effect of CPAP therapy on renal function, they lacked information regarding OSA severity, comorbidities, and treatment adherence. [13] [14] [15] In contrast, betterdocumented but small sample size studies reported a CPAP-positive impact in the short term. [17] [18] [19] [20] In a recent substudy from the Sleep Apnea Cardiovascular Endpoints (SAVE) trial, 200 patients with severe OSA in secondary cardiovascular prevention were randomized to undergo CPAP vs standard medical care for a median of 4.4 years. The sample size was small (200 patients) and likely insufficient to show an effect of CPAP on either eGFR or albumin excretion. 21 To date, the literature has not addressed the respective effect of different modalities of positive airway pressure therapy (eg, fixed CPAP [fCPAP] or autoadjusting positive airway pressure [APAP] ).
Currently, APAP is widely used for OSA therapy. APAP devices deliver variable pressures adjusted to each patient's requirement. Efficacy on symptoms and quality of life, as well as adherence to treatment, are claimed to be similar to fCPAP. 22 However, some data suggest that BP reductions are greater with fCPAP than with APAP, 23, 24 possibly due to a stronger inhibitory effect of fCPAP on sympathetic tone. 25 Such hemodynamic and autonomic effects might have an impact on evolution of renal function. 26 We therefore hypothesized that an effect on kidney function could be more significant in patients treated with fCPAP compared with those receiving APAP.
The European Sleep Apnea Database (ESADA) prospectively records data from unselected adult patients (aged 18-80 years) initially referred to several European sleep centers for suspected OSA. 27 In the present study, we analyzed eGFR in patients of the ESADA who underwent multiple determinations of serum creatinine with the goal of evaluating longitudinal changes in eGFR in untreated patients and in those receiving different CPAP modalities for OSA treatment.
Patients and Methods
Enrollment in the ESADA started in March 2007. Written informed consent to the anonymous use of data was obtained from all patients. Each center obtained approval from the ethical committee of its own institution (e-Appendix 1).
The ESADA registry enables entries of clinical and laboratory data from patients seen at baseline and different follow-up visits. Recorded data include anthropometrics, clinical history, daytime somnolence assessed by using the Epworth Sleepiness Scale, biological parameters, and baseline polysomnography or level 3 cardiorespiratory polygraphy data. The methods used for polysomnography/cardiorespiratory polygraphy scoring have been reported previously. 9, 28 The Chronic Kidney Disease-Epidemiology Collaboration equation was used for eGFR calculation because it usually performs better than other equations, such as the Modification of Diet in Renal Disease Study equation. 29, 30 Data recorded between March 2007 and May 2016 were analyzed. The follow-up time ranged between 1 and 100 months. During the followup period, patients received up to four visits. Baseline data recorded before initiation of OSA treatment and data recorded at the last follow-up visit were analyzed. Data from patients not receiving OSA therapy, or receiving fCPAP or APAP, were analyzed separately.
following the principles applied at each clinic. Follow-up visits were planned at variable time points. Clinical and biological data were collected according to the ESADA standard protocol. Information on adherence to therapy (from machine time counter) was recorded.
Data are reported as mean AE SD or median (interquartile range), as appropriate. Differences in frequency distribution of categorical variables were evaluated by using the c 2 test. A one-way ANOVA and Kruskal-Wallis test were used for group comparisons for normally and nonnormally distributed variables, respectively. Twoway ANOVA was applied to examine the influence of treatment and of its interaction with other categorical variables on DeGFR.
Fisher's protected least significant difference was used for multiple comparisons in ANOVA models. A multiple linear regression model was built to test the effect of treatment (independent variable) on DeGFR (as dependent variable), while adjusting for confounding/effect-modifying variables. In one-and two-way ANOVA and in the multiple model, continuous variables were dichotomized at their 50th percentile (median). All analyses were performed in IBM SPSS Statistics version 20 (IBM SPSS Statistics, IBM Corporation). A P value < .05 was considered statistically significant.
Results
At the time of analysis, the database included 19,665 subjects. Among them, 1,807 patients had creatinine level determinations both at baseline and at a follow-up visit. These patients were classified according to the assigned OSA treatment: 144 patients were assigned to no OSA therapy or were recommended to lose weight (untreated group), 485 were assigned to APAP, and 1,178 to fCPAP. Compared with the 17,858 excluded subjects, the study sample had more severe OSA at baseline; however, the differences in demographic characteristics and comorbidities between samples, although statistically significant, were small (e- Table 1 ). In the fCPAP group, mean therapy pressure was 8.9 AE 2.4 cm H 2 O. In the APAP group, lowest pressure was set at 4.6 AE 1.1 cm H 2 O, and highest at 15.1 AE 2.1 cm H 2 O. Table 1 presents the main characteristics of the included subjects. OSA was less severe and the percentage of subjects with comorbidities was lower in the untreated group than in the APAP or fCPAP group. Systematic differences in apnea/hypopnea index values obtained by using cardiorespiratory polygraphy and polysomnography were in line with those previously reported. 28 Most patients had normal or slightly diminished eGFR.
The follow-up period and change in BMI were similar in all groups. The reduction on the Epworth Sleepiness Scale score was more pronounced in the APAP and fCPAP groups compared with the untreated control group, with no significant differences between the two CPAP modes. CPAP adherence was high and similar in the APAP and fCPAP groups ( Table 2) . Median follow-up duration in the whole sample was 541 days (interquartile range, 220-1,255 days). During the follow-up period, eGFR decreased, although the interindividual variability was high. In unadjusted analyses, eGFR decreased more in older patients and in those with chronic heart failure, higher baseline eGFR, longer follow-up, and milder oxyhemoglobin saturation (SpO 2 ) decreases during the baseline night (Table 3) ; however, among the patients with milder nocturnal hypoxemia, more untreated subjects were represented (12.6% vs 3.5%). Sex, arterial hypertension, diabetes mellitus, BMI, and subjective sleepiness did not significantly influence DeGFR.
Unadjusted analysis showed a slight increase of eGFR in the fCPAP group (0.60 AE 11.13; P < .004 vs untreated and P < .003 vs APAP), whereas eGFR decreased in untreated patients (-2.80 AE 8.81 mL/min/1.73 m 2 ) and in APAPtreated patients (-1.12 AE 10.03 mL/min/1.73 m 2 ). Figure 1 shows DeGFR for each type of therapy after allocation of baseline eGFR into below or above the median value. The strongest reduction in eGFR over time was observed in untreated subjects. In addition, eGFR was reduced among subjects with baseline eGFR above the median (P < .0001 both for effect of therapy and of baseline eGFR). The effect of baseline eGFR did not change with type of therapy (P ¼ .107 for interaction). Pairwise comparisons between treatment groups showed that DeGFR in the untreated patients differed from DeGFR in the fCPAP group (Fisher's protected least significant difference test, Overall, the strongest reduction in eGFR was found in untreated subjects and in those with a longer follow-up (P < .0001 both for effect of therapy and of follow-up length). This analysis revealed a significant interaction between treatment and follow-up duration (P < .0001); in fact, while in the untreated and in the APAP groups, a more pronounced decrease in eGFR occurred in the subjects with longer follow-up, eGFR remained substantially unchanged irrespective of treatment duration in the fCPAP group. Similar to results of the previous analysis, DeGFR differed between the untreated and the fCPAP groups (P ¼ .0004) but not between the untreated and the APAP groups (P ¼ .111).
Finally, a multiple regression analysis was performed,
with DeGFR as the dependent variable, and variables that were significant in univariate analysis (Table 3) together with treatment by APAP, treatment by fCPAP, sex, change in BMI, and main comorbidities as independent variables. We identified older age, female sex, chronic heart failure, higher baseline eGFR, and follow-up time as independent predictors of a reduction in eGFR. Conversely, only treatment with fCPAP was identified as a significant and independent predictor for an increase in eGFR at follow-up, whereas treatment with APAP was possibly associated with only a modest improvement in eGFR (trend P ¼ .087) ( Table 4) . When corrected for other confounders/modifiers, patients treated with fCPAP presented an overall increase of 3.6 mL/min/1.73 m 2 in eGFR compared with untreated patients.
In a sensitivity analysis, the multiple regression model was run after excluding patients with hypertension. The effect of treatment remained unchanged: fCPAP was still significant (B ¼ 3.710; P < .0001) compared with untreated patients, and APAP did not demonstrate a significant impact (B ¼ 1.401; P ¼ .232).
Discussion
It has been shown that eGFR progressively declines in OSA at a rate proportional to nocturnal hypoxemia.
11
Few studies have addressed the effects of CPAP treatment on renal function. Existing studies have been performed on rather small samples of subjects, [17] [18] [19] [20] [21] and, with one exception, 21 were based on short-term followup. In addition, no study has yet separately analyzed fCPAP and APAP effects. The main result of the present study was that in adult patients with OSA, a progressive reduction in eGFR was attenuated by fCPAP, whereas APAP had no significant impact. In addition, advanced age, female sex, and chronic heart failure accelerated the eGFR decline. with follow-up below (red columns) and above (blue columns) median, separately for treatment groups. P < .0001 for both effects of therapy and of follow-up duration. A significant interaction between treatment and follow-up duration was also found (P < .0001, two-way ANOVA). See Figure 1 legend for expansion of other abbreviations.
fCPAP and APAP have been mostly compared regarding their respective effects on adherence, symptoms, and quality of life. Because only marginal nonclinically relevant differences were found for adherence, 22, 31 with similar effects in the correction of sleep respiratory disorders and symptoms, 22,32 the two treatment modalities are usually considered equivalent.
In agreement with previous experiences, we observed similar changes in Epworth Sleepiness Scale scores following fCPAP and APAP. Thus far, less attention has been paid to possible differences between the two treatment modalities on cardiovascular, metabolic, or renal outcomes. Two studies reported a greater reduction in BP following fCPAP than APAP, 23, 24 which was attributed to persistently higher sympathetic activity with APAP compared with fCPAP. 25 We hypothesized that the smaller reduction in sympathetic activity under APAP might translate into smaller BP reduction, endothelial dysfunction, and then a limited effect on eGFR. This scenario was confirmed by our data showing that fCPAP, but not APAP, could attenuate the spontaneous decline of eGFR observed in untreated subjects. We found no differences in BP changes between fCPAP and APAP therapy, but our database only included office BP measurements. In fact, only measurements using ambulatory BP monitoring were statistically different between fCPAP and APAP in a previous study. 24 The superiority of fCPAP for maintaining renal function might be clinically relevant in patients with OSA at risk for renal function decline.
Another important finding was that baseline eGFR affected subsequent eGFR changes in all treatment groups. On average, eGFR decreased in the subjects with higher baseline values, whereas it decreased less, or increased, in those with a lower baseline value. Likewise, in the SAVE study, the rate of change in eGFR was lower in patients with reduced baseline eGFR compared with those with normal baseline eGFR. 21 Previous investigations on eGFR changes following CPAP in small samples of patients reported varying findings depending on the characteristics of the studied patients. Two studies in patients with a mean baseline GFR > 120 mL/min/1.73 m 2 found that GFR decreased after a 1-month treatment period, which was interpreted as improved renal function due to decreased hyperfiltration. 17, 19 Instead, in patients with slightly reduced eGFR (77 AE 12 mL/min/1.73 m 2 ), an increase in eGFR was observed after 3 months with CPAP. 18 In patients with stage 3 to 5 CKD, a slower decrease in eGFR was reported after 0.6 to 3.5 years if compliance to CPAP was > 4 h per day. 20 Therefore, CPAP in OSA may have different beneficial influences on renal function that are not fully revealed by eGFR changes alone.
Although a progressive reduction in GFR occurs in the general population after age 30 to 40 years, 33 whether sex influences the progression of eGFR decline is controversial. [34] [35] [36] In the present study, an independent detrimental effect of female sex on renal function in See Table 1 and 2 legends for expansion of abbreviations.
chestjournal.org OSA was found. In our ESADA cross-sectional study, a significant association was also found between female sex and CKD in OSA. 9 Thus, our data support that OSA can be more harmful to kidney function in women than in men. Further studies may clarify the mechanisms through which sex may influence renal function in OSA.
The other significant determinants of eGFR changes in our sample were age and chronic heart failure, both of which are well-known, important determinants of kidney function loss. 33, 37 Lowest nocturnal SpO 2 was the only parameter of severity of OSA independently related to CKD in our previous cross-sectional analysis. 9 In this study, baseline SpO 2 was not significant in multivariate analysis because only a small number of subjects, mainly with mild to moderate OSA, did not receive any treatment for their respiratory disorders during the follow-up. In univariate analysis, mild hypoxemia was associated with a more marked decrease in eGFR. Subjects with milder hypoxemia also had a lower apnea/ hypopnea index and were more often untreated, which could suggest that even mild to moderate OSA, when left untreated, may be harmful to renal function.
Unexpectedly, no effect of CPAP adherence on DeGFR could be shown. Mean compliance to treatment was high, possibly because our sample represented a selfselected population in which the patients more compliant to treatment were more likely to return for follow-up evaluations. Possibly, a higher number of patients poorly compliant to treatment would be necessary for a more reliable evaluation of the potential compliance effects.
Among patients with hypertension, treated by using either APAP or fCPAP, the most common antihypertensive treatment included drugs acting on the renin-angiotensin system (68.7% and 62.7% of subjects, respectively), either alone or in association with other drugs. The large variety of pharmacologic treatments in the whole sample made the analysis of effects of medical therapy extremely complex. However, the respective effects of fCPAP and APAP were confirmed in normotensive subjects, without the confounding effect of antihypertensive medications.
The present study has important strengths. To our knowledge, it is the first study that evaluated eGFR in response to OSA treatment on a large number of subjects and in the long term. In addition, it may have important clinical implications on the therapeutic management of OSA because it adds some knowledge to the thus far poorly explored field of differential impact of fCPAP and APAP treatment. This study also has limitations. The study population exhibited a higher rate of comorbidities, including hypertension and type 2 diabetes, and more severe sleep apnea syndrome compared with ESADA patients not included in the analysis. Thus, our results may not perfectly fit the whole clinically suspected OSA population. In addition, because > 90% of the subjects were white, our results may not apply to other ethnic groups. Some factors that could influence eGFR evolution, such as inflammatory markers 38 or residual sleep fragmentation during positive pressure application, 26 were not evaluated.
Furthermore, the study lacks additional information on kidney damage such as albuminuria. Finally, we are not aware if GFR estimates were influenced by methods used for creatinine determination in some patients because measurement techniques were not recorded.
Conclusions
In the present study, eGFR progressively decreased in patients with OSA. Although fCPAP and APAP may be similarly effective on daytime sleepiness, only fCPAP may attenuate eGFR decline. This finding, taken together with the previously reported lesser effectiveness of APAP in reducing BP, supports greater benefits of fCPAP on general health status in OSA. This outcome should not discourage treatment with APAP in all patients with OSA but suggests that APAP should not be the first choice for treatment, especially in patients with some comorbidities, such as arterial hypertension or CKD. Further studies are needed to explore if other health aspects that are known to be influenced by OSA (eg, metabolic dysfunction or inflammatory activation) may also be variously affected by fCPAP and APAP, or to verify if different software or settings of APAP may affect long-term APAP effects.
